ABOUT GLUCORAPHANIN

Rydapt has become demonstrated to improve survival in sufferers with AML associated with an FLT3 mutation. 1 key study, involving 717 such people, in comparison Rydapt with placebo (a dummy treatment) to begin with as an addition to other most cancers medicines, followed by cure with Rydapt or placebo by itself in Those people whose illness respond